Dr. Paul appears to be offended by our use of "fooling the brain" to describe the perception of increased airflow after activation of the nasal transient receptor potential (TRP) channel by menthol. Distinct from his example, while opioids directly block pain receptors, TRP channels are part of the cold receptor system. When these channels are activated, it typically produces the sensation of cold and an appropriate physiologic response. However, menthol activation of the TRP-M8 ion channel in the nose is interpreted in the brain as a sensation of increased airflow. While opioids truly block pain, this sensation of increased airflow triggered by menthol is associated with no change in airflow. 3 The clearest description of this would be "fooling the brain."
Finally, on January 9, 2009, while this article was under embargo, Dr. Paul wrote to Mr. Ray Koteras, Director of Technical and Medical Services at the American Academy of Pediatrics (AAP), asking that he share comments similar to those in his letter with key physicians in the AAP. Dr. Paul admitted having a conflict of interest and said he would not be commenting to the media but that his talking points might help others respond to the media. However, within days Dr. Paul gave many media interviews. He told MSNBC "this article is at best incomplete and at worst irresponsible." 4 He told National Public Radio that he takes issue with this study stating, "People for one hundred years have been using VVR and I hear from parents that their parents used it when they were kids and their parents when they were kids." 5 Dr. Paul was quoted by the Business Courier of Cincinnati that this manuscript was "a real stretch." "It's really unbelievable . . . and it really calls into question for me that they had an agenda here," he said. 6 Unlike Dr. Paul, who has received funding from P&G to study VVR in 150 children to determine if this makes then feel better, I could not obtain funding to conduct these studies. This research was performed by Drs. Abanses and Arima using discretionary funds that I pulled together. I am delighted that both of these men are now academic clinician-scientists. If this was my "agenda," I am happy to confess.
I have been impressed with the response of P&G confirming that VVR should never be used in children under the age of 2 nor placed under or in the nose of anyone. They have expressed a genuine interest in learning more about the phenomena that we described. Since the time of publication of this article, there have been nearly 30 additional cases reported to me by parents and physicians from around the world. With the cooperation of P&G, I have urged each of these physicians and parents to report their observations directly to the company. 
Acute Management of Atrial Fibrillation
To the Editor:
Khoo and Lip (March 2009) 1 have reviewed the therapy of acute atrial fibrillation (AAF) extensively. Patients presenting with AAF are very heterogeneous; however, all may show spontaneous conversion to sinus rhythm. The heterogeneity of the disease and its underlying mechanisms makes studies, reviews, and guidelines very complicated and confusing. The review by Khoo and Lip 1 suggests that AAF leading to critical illness is the same as critical illness leading to AAF, and that, therefore, the therapeutic approach can also be the same. In our view, this is not correct.
AAF is a multifactorial disease involving structural cardiac abnormalities, inflammation, electrolyte disturbances, hormonal and autonomous nervous system dysregulation, and fluid imbalance, among others, as underlying causes. A difference in balance between causes in the two types of patients is more than likely. 2 For example, arrhythmias can only develop by the combination of a trigger and a substrate. In outpatient clinic patients with AAF, there might be a larger role for the substrate, while in critically ill patients with AAF the trigger is of utmost importance. In critically ill patients, the underlying trigger should be treated first. Treatment of the underlying disease, pain and anxiety relief, oxygenation, and correction of hemodynamics are mandatory, and this essential therapy leads to conversion to sinus rhythm in the majority of cases without further intervention. Direct current cardioversion, based on our experience and supported by the literature, 3 has no sustainable result if the underlying triggers are not eliminated. Direct current cardioversion therefore, should only be used in really desperate situations, although, as mentioned before, the efficacy remains debatable.
The best pharmacotherapeutic approach is also a point of discussion. However, much experience with a few drugs is probably better than little experience with many drugs, and amiodarone might be the drug with the best range. 2 Most antiarrhythmic drugs, and especially class I drugs, have never been tested in critically ill patients, and their potential adverse effects might be exaggerated just in these patients. Whether magnesium is really effective or just buys time to spontaneous conversion remains to be elucidated. 4 Critically ill patients may have thrombophilia, but they certainly have a high risk of bleeding.. This means that studies and guidelines about prophylaxis for the prevention of thromboembolism for outpatients or other patients cannot be extrapolated. There is no evidence we can rely on for anticoagulant therapy in patients with AAF due to critical illness.
In conclusion, the paucity of data about AAF in critically ill patients should not lead to the extrapolation of guidelines from
